These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 11205900

  • 1. Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients.
    Nikitina EY, Clark JI, Van Beynen J, Chada S, Virmani AK, Carbone DP, Gabrilovich DI.
    Clin Cancer Res; 2001 Jan; 7(1):127-35. PubMed ID: 11205900
    [Abstract] [Full Text] [Related]

  • 2. Human monocyte-derived dendritic cells pulsed with wild-type p53 protein efficiently induce CTLs against p53 overexpressing human cancer cells.
    Tokunaga N, Murakami T, Endo Y, Nishizaki M, Kagawa S, Tanaka N, Fujiwara T.
    Clin Cancer Res; 2005 Feb 01; 11(3):1312-8. PubMed ID: 15709203
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck.
    Eura M, Chikamatsu K, Katsura F, Obata A, Sobao Y, Takiguchi M, Song Y, Appella E, Whiteside TL, DeLeo AB.
    Clin Cancer Res; 2000 Mar 01; 6(3):979-86. PubMed ID: 10741724
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Full-length dominant-negative survivin for cancer immunotherapy.
    Pisarev V, Yu B, Salup R, Sherman S, Altieri DC, Gabrilovich DI.
    Clin Cancer Res; 2003 Dec 15; 9(17):6523-33. PubMed ID: 14695157
    [Abstract] [Full Text] [Related]

  • 9. Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers.
    Imai K, Hirata S, Irie A, Senju S, Ikuta Y, Yokomine K, Harao M, Inoue M, Tsunoda T, Nakatsuru S, Nakagawa H, Nakamura Y, Baba H, Nishimura Y.
    Clin Cancer Res; 2008 Oct 15; 14(20):6487-95. PubMed ID: 18927288
    [Abstract] [Full Text] [Related]

  • 10. Effects of dendritic cells transfected with full length wild-type p53 and modified by bile duct cancer lysates on immune response.
    Sun HW, Tang QB, Tang C, Zou SQ.
    Hepatobiliary Pancreat Dis Int; 2005 Feb 15; 4(1):121-5. PubMed ID: 15730935
    [Abstract] [Full Text] [Related]

  • 11. [Anti-tumor immune response of dendritic cells transfected with wild-type p53 gene].
    Liu HJ, Xin JB, Li ZY, Xiong XZ, Tao XN, Hu Y.
    Zhonghua Jie He He Hu Xi Za Zhi; 2008 Dec 15; 31(12):902-7. PubMed ID: 19134406
    [Abstract] [Full Text] [Related]

  • 12. The use of transgenic mice to generate high affinity p53 specific cytolytic T cells.
    Yu Z, Liu X, McCarty TM, Diamond DJ, Ellenhorn JD.
    J Surg Res; 1997 May 15; 69(2):337-43. PubMed ID: 9224403
    [Abstract] [Full Text] [Related]

  • 13. In vitro anti-tumor immune response induced by dendritic cells transfected with hTERT recombinant adenovirus.
    Chen L, Liang GP, Tang XD, Chen T, Cai YG, Fang DC, Yu ST, Luo YH, Yang SM.
    Biochem Biophys Res Commun; 2006 Dec 29; 351(4):927-34. PubMed ID: 17097054
    [Abstract] [Full Text] [Related]

  • 14. Generation of tumor-specific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells.
    Hoffmann TK, Meidenbauer N, Dworacki G, Kanaya H, Whiteside TL.
    Cancer Res; 2000 Jul 01; 60(13):3542-9. PubMed ID: 10910067
    [Abstract] [Full Text] [Related]

  • 15. Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man.
    Kuball J, Schuler M, Antunes Ferreira E, Herr W, Neumann M, Obenauer-Kutner L, Westreich L, Huber C, Wölfel T, Theobald M.
    Gene Ther; 2002 Jul 01; 9(13):833-43. PubMed ID: 12080377
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
    Bondurant KL, Crew MD, Santin AD, O'Brien TJ, Cannon MJ.
    Clin Cancer Res; 2005 May 01; 11(9):3446-54. PubMed ID: 15867247
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Mutated p53 gene encodes a nonmutated epitope recognized by HLA-B*4601-restricted and tumor cell-reactive CTLs at tumor site.
    Azuma K, Shichijo S, Maeda Y, Nakatsura T, Nonaka Y, Fujii T, Koike K, Itoh K.
    Cancer Res; 2003 Feb 15; 63(4):854-8. PubMed ID: 12591737
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.